

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents  
Washington, D.C. 20231 jc912 U.S. PTO

Atty. Dkt.: 620-149

Date: July 9, 2001

Sir:

07/09/01

Attached for filing is the patent application of:

Inventor: LaThangue

Entitled: **PEPTIDE ANTAGONISTS OF DP TRANSCRIPTION FACTORS**

and including attachments as noted below:

Newly executed Declaration,  Copy of Declaration from prior application,  Abstract  
 46 pages of specification and claims (including 20 numbered claims), and  
 3 sheets of accompanying drawing/s.

Record the attached assignment and return to the undersigned.

Attached is a Power of Attorney.

Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications:

**Application Number**

9626589.7

**Country**

Great Britain

**Day/Month/Year Filed**

20 December 1996

PCT/GB97/03506

22 December 1997

, respectively, the entire content of which is hereby incorporated by reference in this application..

Certified copy(ies) of foreign application(s) is/are attached.

Certified copy(ies) filed on \_\_\_\_\_ in prior appln. no. \_\_\_\_\_ filed \_\_\_\_\_.

Please amend the specification by inserting the following paragraph before the first line: --This application claims the benefit of Provisional Application No. \_\_\_\_\_, filed \_\_\_\_\_, the entire content of which is hereby incorporated by reference in this application.--

Please amend the specification by inserting the following paragraph before the first line: --This application is a  continuation/ division/ continuation-in-part of Application No. 09/308,935, filed May 27, 1999, \_\_\_\_\_, the entire content of which is hereby incorporated by reference in this application.--

Petition filed in prior application to extend its life to insure co-pendency.

The prior application is assigned to Prolifix Limited.

It is hereby requested that the Examiner consider the art cited in the parent application by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached.

Applicant claims "small entity" status.  "Small entity" statement attached.

Please enter the attached and/or below preliminary amendment **prior** to calculation of filing fee:

Also attached:  Information Disclosure Statement;  Non-Publication Request;  Nucleotide and/or Amino Acid Sequence Submission;  Statement deleting Inventor(s) named in prior application;  Other:  
**3 sheets of formal drawings; Abstract**

**FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HEREWITH CANCELED**


Basic Filing Fee		\$	710.00		
Total effective claims	20	- 20 (at least 20) =	0 x \$ 18.00	\$	0.00
Independent claims	1	- 3 (at least 3) =	0 x \$ 80.00	\$	0.00
If any proper multiple dependent claims now added for first time, add \$270.00 (ignore improper)				\$	0.00
				<b>SUBTOTAL</b>	\$ 710.00
					-\$( 0.00)
				<b>SECOND SUBTOTAL</b>	\$ 710.00
					\$ 0.00
				<b>TOTAL FEE ENCLOSED</b>	\$ 710.00

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
 Arlington, Virginia 22201-4714  
 Telephone: (703) 816-4000  
 Facsimile: (703) 816-4100  
 BJS:eaw

**NIXON & VANDERHYE P.C.**  
 By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 

jc986 U.S. PTO  
 09/900147  
 07/09/01

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Atty. Dkt.: 620-149

Date: July 9, 2001

Sir:

Attached for filing is the patent application of:

Inventor: LaThangue

Entitled: **PEPTIDE ANTAGONISTS OF DP TRANSCRIPTION FACTORS**

and including attachments as noted below:

Newly executed Declaration,  Copy of Declaration from prior application,  Abstract  
 46 pages of specification and claims (including 20 numbered claims), and  
 3 sheets of accompanying drawing/s.

Record the attached assignment and return to the undersigned.

Attached is a Power of Attorney.

Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications:

<b>Application Number</b>	<b>Country</b>	<b>Day/Month/Year Filed</b>
9626589.7	Great Britain	20 December 1996
PCT/GB97/03506		22 December 1997

, respectively, the entire content of which is hereby incorporated by reference in this application..

Certified copy(ies) of foreign application(s) is/are attached.

Certified copy(ies) filed on \_\_\_\_\_ in prior appln. no. \_\_\_\_\_ filed \_\_\_\_\_

Please amend the specification by inserting the following paragraph before the first line: --This application claims the benefit of Provisional Application No. \_\_\_\_\_, filed \_\_\_\_\_, the entire content of which is hereby incorporated by reference in this application.--

Please amend the specification by inserting the following paragraph before the first line: --This application is a  continuation/ division/ continuation-in-part of Application No. 09/308,935, filed May 27, 1999, \_\_\_\_\_, the entire content of which is hereby incorporated by reference in this application.--

Petition filed in prior application to extend its life to insure co-pendency.

The prior application is assigned to Prolifix Limited.

It is hereby requested that the Examiner consider the art cited in the parent application by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached.

Applicant claims "small entity" status.  "Small entity" statement attached.

Please enter the attached and/or below preliminary amendment **prior** to calculation of filing fee:

Also attached:  Information Disclosure Statement;  Non-Publication Request;  Nucleotide and/or Amino Acid Sequence Submission;  Statement deleting Inventor(s) named in prior application;  Other:  
 3 sheets of formal drawings; Abstract

**FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HEREWITH CANCELED**


Basic Filing Fee		\$	710.00
Total effective claims	20 - 20 (at least 20) =	0 x \$ 18.00	\$ 0.00
Independent claims	1 - 3 (at least 3) =	0 x \$ 80.00	\$ 0.00
If any proper multiple dependent claims now added for first time, add \$270.00 (ignore improper)			\$ 0.00
<b>SUBTOTAL</b>			\$ 710.00
If "small entity," then enter half (1/2) of subtotal and subtract			-\$( 0.00)
<b>SECOND SUBTOTAL</b>			\$ 710.00
Assignment Recording Fee (\$40.00)			\$ 0.00
<b>TOTAL FEE ENCLOSED</b>			\$ 710.00

Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our **Account No. 14-1140**. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8<sup>th</sup> Floor  
 Arlington, Virginia 22201-4714  
 Telephone: (703) 816-4000  
 Facsimile: (703) 816-4100  
 BJS:eaw

NIXON & VANDERHYE P.C.  
 By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

**Maertens**

Atty. Ref.: **620-149**

Continuation of Serial No. **09/308,935**

Group:

Filed: **July 9, 2001**

Examiner:

For: **PEPTIDE ANTAGONISTS OF DP TRANSCRIPTION  
FACTORS**

\* \* \* \* \*

**July 9, 2001**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:


**REQUEST**

The Office is requested to use the computer-readable copy of the Sequence Listing from the parent Application No. 09/308,935. The attached paper copy of the Sequence Listing is the same as the paper and computer-readable copies of the Sequence Listing filed in the parent Application No. 09/308,935, with the Letter dated December 23, 1999. No new matter has been added.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:



**B. J. Sadoff**  
Reg. No. 36,663

**BJS:eaw**

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100